SCHEMBL1009623

SCHEMBL1009623

COc1ccc(Cn2cc[n+](C)c2)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.49
SIGMAR1 Q99720 1/20 0.48
CA2 P00918 1/20 0.47
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 2/20 0.44
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 3/20 0.43
ATM Q13315 2/20 0.42
PPARG P37231 1/20 0.41
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41
POLB P06746 1/20 0.41
CYP19A1 P11511 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL2194611 0.98 HSP90AA1 (0.48) HSP90AA1SIGMAR1CA2LMNASMN1; SMN2
SCHEMBL1009269 0.80 MAPT (0.46) HSP90AA1SIGMAR1LMNASMN1; SMN2KDM4E
Bromide SCHEMBL2196188 0.78 MAPT (0.45) HSP90AA1SIGMAR1LMNASMN1; SMN2KDM4E
SCHEMBL1011073 0.78 LPO (0.56) SIGMAR1LMNAKDM4EKMT2AALDH1A1
SCHEMBL28159383 0.77 CA2 (0.57) HSP90AA1SIGMAR1CA2LMNASMN1; SMN2
Bromide SCHEMBL2194865 0.77 LPO (0.55) SIGMAR1LMNAKDM4EKMT2AALDH1A1
SCHEMBL2040007 0.74 CYP19A1 (0.51) KMT2ACYP19A1CYP1A2
SCHEMBL30358181 0.74 CYP19A1 (0.51) KMT2ACYP19A1CYP1A2
SCHEMBL16638701 0.74 CYP19A1 (0.47) HSP90AA1LMNASMN1; SMN2KMT2AALDH1A1
SCHEMBL20527547 0.73 LMNA (0.60) CA2LMNASMN1; SMN2KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2268652-B1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2012-12-19 EP disclosed
EP-2268652-A2 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2011-01-05 EP disclosed
WO-2009118475-A2 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-10-01 WO disclosed